Seer, Inc. (NASDAQ:SEER) Shares Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP grew its holdings in shares of Seer, Inc. (NASDAQ:SEER) by 194.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 127,868 shares of the company’s stock after purchasing an additional 84,515 shares during the period. GSA Capital Partners LLP owned approximately 0.21% of Seer worth $252,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of SEER. AQR Capital Management LLC acquired a new position in shares of Seer during the second quarter valued at $30,000. Point72 DIFC Ltd bought a new position in Seer during the second quarter valued at about $35,000. Quadrature Capital Ltd bought a new position in Seer during the first quarter valued at about $56,000. American Century Companies Inc. boosted its stake in Seer by 42.1% during the second quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock valued at $104,000 after buying an additional 18,302 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Seer by 74.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 59,580 shares of the company’s stock valued at $114,000 after purchasing an additional 25,441 shares during the period. 75.20% of the stock is owned by institutional investors and hedge funds.

Seer Trading Up 2.1 %

Shares of NASDAQ SEER opened at $2.43 on Friday. Seer, Inc. has a one year low of $1.51 and a one year high of $2.53. The business has a 50-day moving average price of $2.00 and a two-hundred day moving average price of $1.87. The firm has a market capitalization of $143.29 million, a PE ratio of -1.87 and a beta of 1.45.

Analysts Set New Price Targets

Separately, Morgan Stanley decreased their price target on Seer from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 13th.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.